Nonalcoholic steatohepatitis-associated hepatocellular carcinoma (NASH-HCC) is a malignancy whose incidents are rapidly increasing. However, the mechanisms that drive development of HCC in a steatotic microenvironment remain unknown. Here we report that the obesity-associated protein JCAD is expressed at significantly higher levels in human NASH-HCC specimens compared with pericarcinoma specimens. High JCAD expression was verified in multiple hepatoma cell lines. Forced overexpression of JCAD in hepatoma cells promoted tumor growth and proliferation, whereas JCAD silencing yielded opposite effects. JCAD interacted with the kinase domain of the tumor suppressor kinase LATS2, a core component of the Hippo signaling pathway. JCAD overexpression inhibited the ability of LATS2 to phosphorylate YAP in this pathway, in turn upregulating CCND1 and GLI2 to promote hepatoma cell proliferation. JCAD was induced by fatty acid overload in hepatic cells and was highly expressed in a mouse model of NASH-precarcinoma lesions, where the ratio of phospho-YAP to YAP was decreased. In human NASH-HCC specimens, JCAD expression and YAP phosphorylation patterns paralleled with the mouse model. Our findings illuminate a new role for JCAD and its critical interplay in the Hippo signaling cascade during the transition of NASH to HCC, with potential implications for therapeutic development in this setting.
Introduction
Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of disorders with fat accumulation, from simple fatty liver (SFL), a progressive form of nonalcoholic steatohepatitis (NASH), and fibrosis/cirrhosis to NASH-associated hepatocellular carcinoma (NASH-HCC; ref. 1). In the last few decades, NAFLD has emerged as the major cause of chronic liver disease in most parts of the western world (2) , and approximately 1.0 billion individuals are affected worldwide, ranging from 10% to 36% of the general population (1, 3) . As a liver-associated complication of diabetes, metabolic syndrome, and obesity, NASH requires medical attention, progresses to end-stage liver disease (ESLD or cirrhosis), and is currently the second leading etiology of liver disease in patients awaiting liver transplantation in the United States (4) . NASH-HCC has become the major factor contributing to an increased HCC incidence in the United States (5-7). The multifactorial features of NASH and its progression determine the pathogenic complexity of HCC development in a steatotic microenvironment. Tremendous efforts have already been put into this field to elucidate the role of adaptive immunity through CD8
þ and NKT cells in the development of NASH-HCC in mice fed a high-fat/cholinedeficient diet with a series of knockout manipulations (8) . The crucial role of innate immunity in NASH-HCC development was supported by a recent study that demonstrated that the suppression of Th17 cell differentiation or blocking IL17A signaling prevents NASH and subsequent HCC development (9) . Moreover, an elegant study emphasized the importance of gut microbiota in NASH progression and noted that senescent hepatic stellate cells (HSC) may be critical for the transformation of steatotic hepatocytes to malignant cells (10) . Growing evidence in laboratory studies has narrowed the gap in our understanding of oncogenic processes that occur through genetic and epigenetic control, cellular interactions, and molecular signaling (11) . However, currently available information does not clearly provide a complete understanding of molecular interplays that occur during NASH progression and hepatic carcinogenesis. Both basic and clinical investigations of NASH-HCC have not been able to identify molecular targets for therapeutic intervention or biomarker use, nor have they established guidelines for monitoring the transformation process.
To investigate the progression of NASH to HCC, we established a differential gene expression profile by analyzing significant expression changes in pathologically confirmed NASH-HCC and pericarcinoma specimens using Affymetrix microarrays. An obesity-associated gene, KIAA1462, was selected from the highly expressed genes in NASH-HCC tissues. The nucleotide sequence of KIAA1462 encodes for 1390 amino acids (aa), and no functional domains have been characterized in this protein. Recently, KIAA1462 was identified as a molecular component of endothelial cadherin (E-cadherin)-based cell-cell junctions (12) . Moreover, as a junction protein, the protein of KIAA1462 is associated with coronary artery disease (13, 14) . Hence, the protein of KIAA1462 is named as junctional protein-associated with coronary artery disease (JCAD). The JCAD sequence is highly conserved in vertebrates from zebrafish to human (12) , which indicates that the protein may have an important biological function. JCAD has been recently thought to be a novel candidate gene for a pathogenic role in serous borderline tumorigenesis (15) . To our knowledge, its participation in oncogenesis has not been explored yet, nor has the role of JCAD in hepatic pathophysiology and carcinogenesis been investigated.
In the current study, we examined the role of JCAD in modulating tumorigenesis by manipulating its expression levels in hepatoma cells, determining its interaction with large tumor suppressor kinase 2 (LATS2), and inhibiting its kinase activity to influence HCC cell proliferation. Moreover, we employed a mouse model of NASH-precarcinoma lesions and human NASH-HCC specimens to verify findings from other systems. Our findings suggest that JCAD may have potential to serve as a valued biomarker in the progression of NASH to HCC and may facilitate the development of targeting therapeutics in improving the outcome of NASH-HCC treatment.
Materials and Methods

Human NASH-HCC specimens
Paraffin-embedded paired tumor and pericarcinoma tissues (n ¼ 12) were obtained from the Biorepository of Fudan University Institute of Liver Cancer. Only four pairs of specimens with sufficient RNA quantity and quality were used for the Affymetrix microarray analysis, and the remaining RNA was enough to detect JCAD expression by qRT-PCR. Ten pairs of additional NASH-HCC frozen specimens were obtained in the same way and were stored at -80 C immediately after resection. All patients who underwent surgical resection were diagnosed with NASH-HCC without HBV or HCV infection and alcoholic liver disease, and provided written informed consent for the use of tissue specimens in medical research when the specimens were collected in the biorepository. The use of human tissue was approved by the Ethic Committee of Fudan University School of Basic Medical Sciences, and followed guidelines of the Helsinki Declaration and the national, municipal, and university regulations.
Animals
Male mice of C57BL/6J strain (8-12 weeks of age) were purchased from Nanjing University Institute of Animal Models (Nanjing, China), used to establish model of NASH-precarcinoma lesions. Male BALB/c nude mice (4-5 weeks of age) from Slack Company were used to establish a subcutaneous xenograft tumor model. All mice were housed in a specific pathogen-free facility with 12-hour light/dark cycle at [21] [22] [23] C. All animal experimental protocols were approved by the Animal Ethic Committee of Fudan University School of Basic Medical Sciences, and performed in the line with NIH Guidelines for Experimental Animal Handling and Use, as well as the national, municipal, and university regulations.
Cell culture
Huh Cell proliferation assay A water-soluble tetrazolium salt (WST-1) reagent (Sigma Aldrich) was used to determine the proliferation rate of different cells. Five thousand cells in 100 mL of medium were plated in each well of a 96-well plate and incubated overnight. The next day, 10 mL WST-1 reagent was added. After a further incubation of 4 hours, optical density (OD) was measured spectrophotometrically at a wavelength of 450 nm, and the background was corrected at 650 nm. At least three experiments were repeated independently in triplicate.
The YAP phosphorylation assay in JCAD-transfected cells
To determine the effect of JCAD on LATS2-mediated YAP phosphorylation at Ser127, 293T cells were seeded into 6-well plates and transfected in combination of HA-YAP with HA-MST2 (MST2 is an activator of LATS2, and it acts as a positive control), HA-JCAD or a control vector by Lipofectamine 2000 (Thermo Fisher Scientific) according to a previous report with some modifications (17) . Thirty-six hours after transfection, cells were lysed in lysis buffer (25 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% NP40, 5% glycerol; pH 7.4) containing 1Â protease inhibitor cocktail and 1Â phosphatase inhibitor cocktail. The lysates were centrifuged at 12,000 Â g for 10 minutes at 4 C. After measured protein concentration by a bicinchoninic acid assay (BCA) kit (Thermo Fisher Scientific), 30 mg of protein lysate was mixed with 5Â SDS sample buffer, boiled for 10 minutes at 100 C, and subjected to electrophoresis.
Kinase assays
To further detect the effect of JCAD on LATS2 kinase activity, 293T cells seeded in 6-well plates were transfected with a combination of Myc-LATS2 and HA-MST2, HA-JCAD or a control vector using Lipofectamine 2000 (18) . Thirty-six hours after transfection, cells were lysed in immunoprecipitation buffer (25 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% NP40, 5% glycerol, pH 7.4), and the immunoprecipitated LATS2 was captured by Myc-tag magnetic beads. The immunoprecipitated LATS2 protein was subjected to a kinase assay in 30 mL of kinase assay buffer containing 25 mmol/L Tris-HCl, pH 7.4; 1 mmol/L DTT; 10 mmol/L MgCl2; and 1 Â protease inhibitor, supplemented with 500 mmol/L ATP (AMRESCO) and 1 mg of His-YAP expressed in Escherichia coli as the substrate. The reaction mixture was incubated at 30 C for 30 minutes, stopped by addition of 5Â SDS loading buffer, boiled for 10 minutes at 100 C, and subjected to Western blot analysis for the detection of p-YAP.
Xenograft growth in nude mice
To detect tumor growth in vivo, a total of 2.5 Â 10 6 Huh-7 (JCAD-KD and control) and 3.0 Â 10 6 SMCC-7721 (JCAD-OE and control) cells were inoculated into franks of nude mice subcutaneously, respectively. Tumor volume and body weight were measured every five days after inoculation. Mice bearing xenografts were humanely sacrificed in accordance with guidelines approved by the Animal Ethic Committee of Fudan University School of Basic Medical Sciences 20-25 days after the inoculation for further analysis.
Animal model of NASH-precarcinoma lesions induced by a high-fat/calorie diet plus high fructose and glucose C57BL/6J mice were fed a high-fat/calorie (HFC) diet ad libitum with the consumption of high levels of fructose and glucose (23.1 g/L D-fructose plus 18.9 g/L D-glucose) in drinking water for 12 months, as described previously (2) . The diet was obtained from RESEARCH DIET, with 60% kcal from fat and containing 0.1% cholesterol. Mice fed a regular chow diet were used as controls. The mice were humanely sacrificed after 5, 9, and 12 months of feeding, and liver specimens were collected for histopathologic analysis and determination of JCAD expression and p-YAP/YAP ratio.
Statistical analysis
All experiments were repeated at least for three times independently and the results were expressed as means AE SEM. Statistical analysis was performed using SPSS program version 17.0. Normal distribution was performed in all data. Numerical data in a normal distribution between two groups were analyzed by a variance test of homogeneity, then by Student t test. Data between two groups that do not stay in a normal distribution were analyzed by nonparametric Mann-Whitney U test. P value less than 0.05 was considered to be statistically significant.
Results
JCAD was highly expressed in NASH-HCC specimens
To investigate the differentially expressed genes in NASH-HCC specimens, we established a gene expression profile from four sets of NASH-HCC and pericarcinoma specimens using Affymetrix microarrays. Functional analysis (GO enrichment) of the differentially expressed genes indicated that they are involved in protein binding, cell migration, differentiation and adhesion, as well as junction anchoring (Fig. 1A) . Then we observed a striking difference in expression of 26 genes (12 downregulated and 14 upregulated) concerning inflammation, oncogenesis, and angiogenesis between NASH-HCC and pericarcinoma tissues (Fig. 1B) . The most differentially expressed genes included those that were downregulated, such as CNOT6L (cell proliferation, decreased by 90%) and CLEC4M (immune surveillance, decreased by 80%), and those that were upregulated, such as JCAD (adhesion junction, increased up to 6-fold), CD36 (angiogenesis, inflammatory response, fatty acid metabolism, increased up to 7-fold), and ZMYND11 (transcriptional repression and activation, increased up to 10-fold; Fig. 1C ).
JCAD promoted hepatoma cell proliferation and increased colony formation and spheroid formation in vitro
Quantitative RT-PCR verified that JCAD was highly expressed in NASH-HCC compared with pericarcinoma tissues in an increased number of NASH-HCC specimens, as shown in Fig. 2A . We further confirmed JCAD expression in 10 hepatoma cell lines using immortalized hepatocellular L02 cells as a control by a quantitative RT-PCR assay. JCAD was highly expressed in many hepatoma cell lines, especially in Huh-7 (42-fold), Huh-7-Trans (13-fold), HLE (10-fold) and HLF (6-fold) cells, whereas a relatively low expression level was seen in SMCC-7721 (1.3-fold) and SK-Hep1 (2-fold) cells compared with L02 cell line ( Fig. 2B and C) .
To further investigate the biological function of JCAD in hepatoma cells, we inhibited basal expression of JCAD in Huh-7-Trans, Huh-7, HLE, and HLF cells or overexpressed JCAD in SMCC-7721 cell. qRT-PCR and Western blot results confirmed the successful knockdown by an RNAi approach (approximately 70%-80% decrease) or overexpression of JCAD (approximately 60-fold increase) by lentiviral transduction with the full sequence of JCAD in these cell lines ( Fig. 2D and E; P < 0.05).
To investigate the tumorigenic role of JCAD in hepatoma cells with JCAD-KD or JCAD-OE, a WST-1 assay was used to examine the effect of JCAD on proliferation of hepatoma cells. The proliferation of hepatoma cells with JCAD-KD was markedly suppressed in comparison with the control cells, except for HLF cells, probably due to a lower basal JCAD expression in HLF cells than in Huh-7 and Huh-7-Trans cells. In contrast, proliferation of hepatoma cells with JCAD-OE was strikingly enhanced compared with that of the control cells ( Fig. 2F ; P < 0.05).
To further confirm the role of JCAD in tumorigenesis in vitro, we performed a colony formation experiment with stable JCAD-KD or JCAD-OE cells and corresponding control cells. The colony formation of hepatoma cells with JCAD-KD was much lower than that of control cells (down by 60%-70%), whereas JCAD overexpression markedly enhanced colony formation (enhanced up to approximately 2-fold; Fig. 2G ; P < 0.05). Moreover, spheroid formation was used to further verify tumor formation potential (Fig. 2H) . The spheroid formation of hepatoma cells (Huh-7-Trans, Huh-7) with JCAD-KD was much lower than that of cells transfected with a control lentivirus; whereas JCAD-overexpressing cells (SMCC-7721) exhibited enhanced capability of spheroid formation (P < 0.05). However, as shown in Fig. 2H , there was no significant difference between HLE-KD cells or HLF-KD cells and their control cells, which may be due to a lower basal JCAD expression in HLE and HLF cells compared with that in Huh-7 and Huh-7-Trans cells. In summary, our data demonstrated that JCAD promotes the proliferation and tumor formation in vitro.
JCAD promoted xenograft growth in vivo
To further investigate whether JCAD might regulate hepatoma xenograft growth in vivo, Huh-7 with stable JCAD-KD and SMCC-7721 with JCAD-OE and their corresponding control cells were subcutaneously injected into athymic nude mice, respectively. JCAD silence resulted in an approximate 40% reduction in weight and 20% reduction in size of xenograft tumors compared with those of control xenografts ( Fig. 3A and B ; P < 0.05). The xenograft tumors derived from JCAD-KD cells appeared to be morphologically different from control cell-derived tumors, as determined by a histologic analysis (Fig. 3C) , indicating that JCAD-KD could repress tumorigenesis. qRT-PCR and Western blot analyses confirmed the persistent reduction in JCAD expression levels in xenograft tumors ( Fig. 3D and E; P < 0.05). Mice injected with JCAD-overexpressing cells exhibited a 2-fold increase in the weight and 3-fold increase in size of xenograft tumors compared with those of control xenografts ( Fig. 3F and G; P < 0.05). Histologically, tumors derived from JCAD-OE cells appeared to have a higher cell density, as reflected by more nuclei in xenografts, than those derived from control cells (Fig. 3H) , indicating that JCAD-OE could enhance tumorigenesis. qRT-PCR and Western blot analyses confirmed an increase in JCAD levels in dissected xenograft tumors compared with that in control xenografts ( Fig. 3I and J; P < 0.05). The extent of reduction or increase in HCC xenograft growth was consistent with the growth rate of hepatoma cells with JCAD knockdown or overexpression observed in vitro. Altogether, these results indicate that JCAD is involved in hepatoma cell growth in vitro and in vivo, further confirming its prooncogenic function in hepatoma cells. JCAD was highly expressed in NASH-HCC specimens. A, GO enrichment analysis of the differentially expressed genes in NASH-HCC and pericarcinoma tissues. Color indicates the fold change, and expression level increases from blue to orange, as indicated in the scale bar. Dots, triangles, and squares represent biological processes, cellular components, and molecular function, respectively, whereas the size of the shape indicates the number of genes. B, Differential expression of significant genes (including upregulated and downregulated genes) from NASH-HCC specimens is shown in a heatmap. The red color represents enhanced expression, whereas the green represents decreased expression, as indicated in the scale bar. C, Fold changes in gene expression levels compared with those in paired pericarcinoma liver tissue. The red color represents genes with upregulated expression, whereas the green represents genes with downregulated expression. To reveal the physiologic function of JCAD, we firstly investigated the colocalization of JCAD with LATS2, which is a negative regulator of YAP in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor growth. Immunofluorescent staining revealed that JCAD was colocalized with LATS2 in proximity to the nuclear membrane in 293T and Huh-7 cells (Fig. 4A) . We performed a coimmunoprecipitation assay by overexpressing HA-JCAD and Myc-LATS2 in 293T cells or overexpressing Myc-LATS2 in Huh-7-Trans and Huh-7 cells (both of which overexpressed JCAD), and then analyzed the isolated protein complexes by Western blot analysis using a JCAD antibody. The results documented that JCAD interacts with LATS2 in 293T, Huh-7-Trans, and Huh-7 cells, as indicated by the arrow (Fig. 4B) . MOB is another important regulator of the Hippo signaling pathway, and interacts with LATS2 to promote its activation. We also examined whether JCAD affects LATS2 interaction with MOB. As shown in Supplementary Fig. S1A , JCAD did not affect the interaction of LATS2 with MOB. In addition, it seemed that JCAD did not interact directly with MOB neither (the data not shown). There are four functional domains of LATS2 based on its peptide sequence (Fig. 4C) . To determine which domain of LATS2 interacts with JCAD, we constructed different constructs with multiple deletion mutations in LATS2 domains (17) . As indicated by the arrow in Fig. 4D , a coimmunoprecipitation assay with an HA-tag antibody verified that JCAD bound to the kinase domain of LATS2 (amino acids 668-974), which was predicted to be catalytically inactive and adjacent to the MOB1-binding region.
In the Hippo signaling pathway, LATS2 acts as a protein serine/ threonine kinase that phosphorylates YAP to regulate downstream effects. We therefore examined whether the interaction of JCAD affects the kinase ability of LATS2, a His-tagged fusion protein His-YAP was expressed in Escherichia coli and purified as a substrate. We then measured the phosphorylation level of His-YAP by a p-YAP (s127) antibody. JCAD expression decreased LATS2 kinase activity, as demonstrated by the inhibition of YAP phosphorylation (shown by the arrow; Fig. 4E ). Moreover, in JCAD-transfected cells, HA-JCAD markedly suppressed YAP phosphorylation compared with those transfected with a control plasmid and a positive control plasmid HA-MST2, as indicated by the arrow (Fig. 4F) . In this assay, HA-MST2 was used as a positive control to activate LATS2 kinase activity of the phosphorylation on YAP.
JCAD induced dephosphorylation and nuclear localization of YAP
To investigate the JCAD effect on the ability of LATS2 to phosphorylate YAP and further determine whether JCAD acts as a regulator in the Hippo signaling pathway to regulate hepatoma cell proliferation, we examined the expression levels of LATS2, CCND1, GLI-2, p-YAP, and YAP in JCAD-KD and JCAD-OE cells.
As shown in Fig. 5A and B, p-YAP was upregulated in JCAD-KD cells and downregulated in JCAD-OE cells, whereas LATS2 and YAP did not significantly change. JCAD only affected kinase activity of LATS2 by interacting with the kinase domain, but not altering its expression. TAZ is another important regulator that has a function similar to YAP in the Hippo signaling pathway. Hence, we determined expression levels of TAZ and p-TAZ in JCAD-KD and JCAD-OE cells. As shown in Supplementary  Fig. S1B , JCAD did not affect expression levels of both TAZ and p-TAZ. Moreover, expression levels of downstream genes, CCND1 (decreased by 60%) and GLI-2 (decreased by 30%), were downregulated in hepatoma cells with JCAD-KD compared with control cells (P < 0.05); meanwhile, the levels of CCND1 (increased up to 1.5-fold) and GLI-2 (increased up to 1.6-fold) were upregulated in hepatoma cells with JCAD-OE compared with control cells (P < 0.05). To exclude possible offtargeting effects of JCAD shRNA silencing, the functional recovery by reexpressing JCAD with the modified cDNA was performed in JCAD-KD cells (Huh-7-Trans, HLE, and HLF; Supplementary Fig. S2A ). As shown in Supplementary Fig. S2B and S2C, JCAD was reexpressed in JCAD stable knockdown cells. Proliferation was restored in JCAD reexpressed cells as indicated by WST-1 assay shown in Supplementary Fig. S2D . Moreover, expression level of p-YAP was downregulated accordingly in JCAD reexpressed cells ( Supplementary Fig. S2E) ; meanwhile, the downstream genes (CCND1 and GLI-2) of the Hippo signaling pathway were upregulated. This recovery assay further confirmed that the reduction of JCAD expression was specifically responsible for decreased cell proliferation in JCAD-KD cells. The altered expression of YAP target genes (CCND1 and GLI-2) in combination with the results of the above recovery experiment indicate that JCAD may indeed act as a novel upstream regulator of the Hippo signaling pathway to affect hepatoma cell proliferation.
YAP is transcriptionally active when it is translocated into the nucleus (19) . The dephosphorylation of YAP promotes YAP nuclear translocation and upregulates the YAP/TEAD association, leading to YAP/TEAD transcriptional activation, and activates target gene (GLI2 and CCND1) expression (20, 21) . Therefore, we addressed whether JCAD affected YAP nuclear translocation. In Huh-7 and Huh-7-Trans control cells, endogenous YAP was localized in the nucleus (Fig. 5C ). However, JCAD knockdown caused a dramatic redistribution of YAP from the nucleus to the cytoplasm (Fig. 5C) as showed with arrows, especially in Huh-7 cells. In contrast, JCAD overexpression increased YAP nuclear translocation, although not so dramatically. This was confirmed by Western blot analysis with cytosolic and nuclear fraction protein extracts. As shown in Supplementary Fig. S3 , knockdown of JCAD reduced the level of nuclear YAP; at the same time, remarkably increased the relative level of YAP phosphorylation in the cytosolic compartment in Huh-7 cells. These results suggest that JCAD may cause YAP nuclear translocation through phosphorylation by LATS2. 
JCAD was induced in hepatic cells with free fatty acid overload
As mentioned above, JCAD is associated with obesity and highly expressed in NASH-HCC specimens. To determine whether fatty acid overload affects JCAD expression, we treated immortalized L02 hepatocytes, Huh-7, and HepG2 hepatoma cells by free fatty acid (FFA) overload. Oil Red O staining confirmed lipid droplet accumulation after FFA overload (Fig. 6A) . JCAD was highly expressed in these FFA-overloaded cells at both mRNA and protein levels compared with the control cells (P < 0.05; Fig. 6B and C), although how JCAD influences lipid metabolism is unknown. Together, these results indicate that JCAD could be induced in hepatic cells with free fatty overload.
JCAD was increased and the ratio of p-YAP over YAP was decreased in a mouse model of NASH-precarcinoma and NASH-HCC human specimens
We next examined JCAD expression in a mouse model of NASH-precarcinoma lesions and human specimens. First, liver histology and Oil Red O staining in frozen sections from mice fed a high-fat diet plus high fructose and glucose in drinking water for 5, 9, and 12 months indicated steatohepatitis, severe fibrosis, and dysplasia in hyperplastic nodules (other indicators confirmed by a separate investigation; Fig. 7A ; ref. 22) . As shown in Fig. 7B , JCAD expression was upregulated throughout the entire feeding period, while the ratio of p-YAP over YAP was downregulated. JCAD expression increased gradually with the severity of liver steatosis and fibrosis as well as the occurrence of dysplasia (1.9-fold increase at 5 months, 2.2-fold increase at 9 months, and 2.6-fold increase at 12 months), while the ratio of p-YAP over YAP decreased with NASH progression (60% decrease at 5 months, 40% decrease at 9 months, and 70% decrease at 12 months). Moreover, we performed qRT-PCR analysis to detect the core regulators of the Hippo signal pathway in the development of NASH-HCC animal models (5, 9, and 12 months). As shown in the Supplementary Fig. S4 , expression levels of core regulators of Hippo signaling molecules, such as LATS2 and MST1/2 were lower (P < 0.05-0.01) along with the development of NASH-HCC; whereas, YAP, TAZ, and CCND1 appeared to be upregulated compared with the early stage (5 months). Therefore, these results further demonstrate that JCAD was highly upregulated during the transition from NASH to premalignant lesions of HCC and that other components of the Hippo signaling pathway were probably also involved in an intermediate stage of this transition in these animals.
To further determine whether JCAD overexpression occurs in human patients with NASH-HCC, we obtained additional ten pairs of human NASH-HCC and pericarcinoma specimens. JCAD expression was higher in five out of ten HCC specimens than that in the corresponding pericarcinoma tissue (Fig. 7C, sample no. 2,  5, 6, 8, and 9) . Furthermore, the ratio of p-YAP over YAP was lower in these five sets of NASH-HCC specimens with higher JCAD expression as evaluated by Western blot analysis, although heterogeneity in expression of JCAD, YAP, and p-YAP was observed in different NASH-HCC specimens. Therefore, these results demonstrate that JCAD was highly upregulated in half of the analyzed human NASH-HCC specimens and may be involved in the development of NASH to HCC through the Hippo signaling pathway, although the exact mechanisms require further investigation and heterogeneity exists in terms of JCAD expression levels and involvement of the Hippo signaling pathway.
Discussion
NAFLD becomes one of the most common liver diseases in developed and developing countries and represents an increasing epidemic (23, 24) . Its most active form, NASH, is believed to be a potential precursor of HCC (25) . From limited clinical data, it appears that prognosis, risk factors and histopathologic features of NASH-associated HCC are obviously different from those secondary to other etiologies of liver disease, such as hepatitis B or C viral infection (1) . Moreover, pathogenic factors contributing to the oncogenic process in a steatotic microenvironment are considered to differ from HBV or HCV infection, and have been largely undefined yet (26) . Therefore, tremendous efforts are still demanded to understand hepatic carcinogenesis of NASH-HCC at the genetic, epigenetic, molecular, and cell levels in both laboratory and clinical settings.
In this study, we report a novel NASH-HCC candidate gene, KIAA1462, which encodes the JCAD protein identified as a molecular component of E-cadherin-based endothelial cell-cell junctions (12) . As a junction protein, JCAD was shown to enhance tumor cell proliferation and growth in hepatoma cells and in nude mice in the current study (Figs. 2 and 3 ). Our finding also demonstrated that JCAD interacted with LATS2 (Fig. 4B) , which is a core kinase component of the Hippo signaling pathway, encodes a Ser/Thr protein kinase and plays a critical role in mediating the progression of various malignant tumors, such as malignant mesothelioma and nasopharyngeal carcinoma (27) (28) (29) (30) . The Hippo signaling pathway consists of a core kinase cascade (MST1/2, MOB1/2 and LATS1/2) and controls organ size through the regulation of cell proliferation and apoptosis (31) . When the Hippo signal pathway was activated, MOB1/2 interacts with and activates LATS2. Our findings indicated that JCAD directly interacted with LATS2 (Fig. 4B) , and inhibited LATS2 to phosphorylate YAP to induce cell proliferation ( Fig. 4E and F) . We have found that JCAD did not affect the binding of MOB1/2 to LATS2 ( Supplementary Fig. S1A ), nor did it interact with MOB1/2 directly (data not shown). Up to date, we have not found the upstream regulators of JCAD. However, our preliminary results suggest that accumulation of fat acids in hepatic cells upregulated JCAD interacted with LATS2 and inhibited the ability of LATS2 to phosphorylate YAP. A, Representative confocal micrographs of the colocalization of JCAD (green) with LATS2 (red). DAPI (blue) was used for nuclear staining. Scale bars, 5 mm. The green and red color is overlaid in the proximity of the nucleus. B, Myc-LATS2 and HA-JCAD were individually or cotransfected into 293T cells; only Myc-LATS2 was transfected in Huh-7-Trans and Huh-7 cells (which highly expressed JCAD). Thirty-six hours after transfection, Myc-tag was immunoprecipitated, followed by Western blot analysis using JCAD antibodies as indicated by the arrows. The inputs are shown at the bottom. C, A schematic illustration of LATS2 deletion mutation constructs used in this study. D, Full-length HA-JCAD, Myc-LATS2, and deletion mutants were ectopically expressed, followed by Myc-tag-immunoprecipitations and Western blot analysis with HA (as indicated by an arrow) and Myc antibodies. IgG was used as a positive control. Inputs are shown in the bottom panel. E, Kinase activity assay was used to detect the effect of JCAD on LATS2. His-YAP was expressed in Escherichia coli and purified as a substrate. MST2 was used as a positive control to activate LATS2. JCAD expression. Furthermore, JCAD binds to the kinase domain of LATS2 to reduce phosphorylation of YAP, which is a downstream effector and a transcriptional coactivator in the Hippo signaling pathway (32) . The dephosphorylation of YAP promoted YAP nuclear translocation and upregulates the YAP/TEAD association, leading to YAP/TEAD transcriptional activation and proliferation in hepatoma cells ( Fig. 7D; refs. 20, 21 ). TAZ exhibits a function similar to YAP; however, our findings showed that JCAD did not affect TAZ and its phosphorylation in JCAD-manipulated cells (Supplementary Fig. 1B) . The phosphorylation is a critical step in the Hippo signaling process because phosphorylation of YAP prevents its translocation into the nucleus to activate downstream target genes (such as CCND1 and GLI-2), which are associated with cancer development, metastasis, and drug resistance as demonstrated in our previous studies (16, 33, 34) . In this study, we confirmed that expression levels of CCND1 and GLI-2 were upregulated when JCAD was highly expressed. Taken together, our results indicate that JCAD may play an important role by interacting with LATS2 to prevent it from phosphorylating YAP, leading to CCND1 and GLI-2 upregulation and the promotion of HCC development.
The KIAA1462 gene is located on chromosome HSA10p11.23, which harbors a major quantitative trait locus linked to or associated with morbid obesity (35) (36) (37) . The protein of KIAA1462, JCAD was highly expressed in NASH-associated HCC specimens and its expression is inducible by fatty acid overload. Thereafter, we investigated JCAD expression during NASH progression in a mouse model of NASH-precarcinoma lesions (22) .
The sustained JCAD increase and the reduced p-YAP/YAP ratio in the livers of mice with NASH-precarcinoma lesions and in NASH-HCC specimens underscore the significance of the Hippo signaling pathway in NASH-HCC development, which has not been previously reported in the literature. Interestingly, the molecular weight of JCAD appeared to increase in mice with NASH progression (Fig. 7B) . The exact mechanisms underlying this finding is unclear, however, our speculation is that as a phosphoprotein, JCAD may be posttranslationally phosphorylated at amino acid sites 1044, 1050, 1194, and 1281 in a steatotic environment. Given the limited availability of clinical specimens, the data from the current study did not allow us to correlate JCAD expression and YAP dephosphorylation with NASH-HCC histopathologic type, tumor size and number, aggressiveness, metastasis, and prognosis. Therefore, more investigations are warranted to explore the mechanism of progression from NASH to HCC.
To facilitate the understanding role of JCAD in the transition of NASH to HCC, an illustration is shown in Fig. 7D . In normal liver tissues, JCAD is maintained at a low level. When fatty acids are accumulated in the liver, high JCAD expression is induced. The excess JCAD markedly inhibits the ability of LATS2 to phosphorylate YAP. Phosphorylated YAP is retained in the cytoplasm, whereas unphosphorylated YAP is translocated into the nucleus to activate downstream genes, such as GLI-2 and CCND1, which are morphogenic and proliferative to many cell types (33) .
In conclusion, JCAD appears to be involved in the transition from NASH to HCC through the Hippo signaling pathway by interacting with LATS2 and inhibiting its kinase activity to JCAD was highly expressed in a mouse model of NASH-precarcinoma lesions and human NASH-HCC specimens. A, Representative images of hematoxylin and eosin (H&E) and Oil Red O staining of mouse NASH-precarcinoma liver tissues collected after 5, 9, and 12 months of feeding a high-fat diet plus high glucose/fructose in drinking water (magnification, Â 40). Scale bars, 10 mm. B, Western blot analysis of JCAD protein levels in different stages of mouse liver tissues (n ¼ 3 per group). The ratios of JCAD over b-actin and p-Yap over Yap are shown, with the control set to 1.0. C, Western blot analysis of JCAD in NASH-HCC and pericarcinoma specimens (n ¼ 10 per group). The ratios of JCAD over b-actin and p-YAP over YAP are shown, with the control set to 1.0. D, A schematic illustration to indicate the involvement of JCAD in the Hippo pathway signaling, which contributes to the transition from NASH to HCC. JCAD acts as an upstream regulator, binds to LATS2, whereas it did not affect the interaction between JCAD and MOB, which normally binds to LATS2. The interaction between JCAD and LATS2 affects the kinase activity of the latter and reduced YAP phosphorylation status. Dephosphorylation of YAP leads to its nuclear translocation and binds to TEAD to activate the downstream genes (such as CCND1 and GLI-2) transcription; meanwhile the phosphorylated YAP binds to 14-3-3 and results in its cytoplasm retention. Consequently, through the Hippo signaling pathway, JCAD contributes to cell proliferation and tumor formation in a steatotic microenvironment. modulate cell proliferation and morphogenic process. Therefore, JCAD was identified as an oncogenic facilitator that promotes morphogenic and proliferative responses in a steatotic microenvironment. Our findings underscore that JCAD has great potential to indicate the progression of NASH to HCC, and that the Hippo signaling pathway may well be the candidate for intervention by molecular targeting therapeutics.
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